| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Autoimmune movement disorders
Personalized treatment
for each patient
Autoimmune movement disorders encompass a large and diverse group of neurologic disorders occurring either in isolation or accompanying more diffuse autoimmune encephalitic illnesses. Disorders may be ataxic, hypokinetic (parkinsonism), or hyperkinetic (myoclonus, chorea, and other dyskinetic disorders).
Given the variety of movement phenomena and disorders, treatment protocols should be individualized for each patient and reflect symptom severity, the type of antibody identified, and the presence or absence of cancer. In addition to oncologic therapy (when appropriate), treatment often involves immunotherapy and symptomatic therapy. Often, early initiated immunotherapy gives patients the best possible outcomes.
Expert developed, clinically actionable evaluations
Mayo Clinic Laboratories' comprehensive autoimmune movement disorders panel is continuously updated to include newly discovered antibody biomarkers and uses advanced testing approaches to detect actionable antibodies. Test results can help guide treatment selection, which can involve oncologic therapy (when appropriate) as well as immunotherapy and symptomatic therapy.
Ma2-directed illness
Mayo Clinic Laboratories has optimized detection of Ma2-associated autoimmune encephalitis through development of an innovative, enzyme-linked immunosorbent assay.
Stiff-person spectrum disorders
Learn more about Mayo Clinic Laboratories’ pioneering Stiff Person Spectrum Disorders evaluation, the first commercially available evaluation of its kind to test for all relevant biomarkers for stiff-person spectrum disorders.
By the numbers
9
Novel Antibodies Offered Only At Mayo Clinic Laboratories: KLHL11, GFAP, Septin-5, Septin-7, Neurochondrin, AP3B2, GRAF1, NIF, & GlyR
53%
of autoimmune cerebellar ataxia is paraneoplastic
46%
of autoimmune cerebellar ataxia patients improve with immunotherapy
When to consider testing
Consider autoimmune testing for patients presenting with a movement disorder and one or more of the following:
Key testing
Advantages
Additional testing
Phenotypic evaluations
Our autoimmune movement disorder evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.
The role of Kelch 11
The groundbreaking discovery — by a team of researchers that included Mayo Clinic scientists — that testicular cancer-associated paraneoplastic encephalitis is caused by KLHL11 autoantibodies paved the way for development of the world’s first evidence-based test to confirm the presence of Kelch-like protein (KLHL11) autoantibodies.
Testicular cancer-associated paraneoplastic encephalitis is often misdiagnosed due to neurological syndrome symptoms preceding tumor detection. Identification of KLHL11 autoantibodies, which seems to be one of the most common paraneoplastic antibodies in men, enables providers to offer specific treatment protocols, such as cancer treatments and immunosuppressive therapies, to manage and treat the disease. Early and accurate diagnosis of this syndrome is critical for disease stabilization and possible reversal.
Novel biomarkers added to movement disorders profile
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Articles and resources
